Actos Patent Expiry Fuels Takeda's Drive For Deals - Licensing Exec
This article was originally published in PharmAsia News
Executive Summary
Takeda is looking to partner with companies owning late-stage compounds in an effort to replace revenue that will likely be lost following U.S. patent expiry of its blockbuster type 2 diabetes treatment Actos (pioglitazone), according to General Manager of Global Licensing & Business Development Hiroaki Ogata